[A18-49] Emicizumab (haemophilia A) - Addendum to Commission A18-20
Last updated 20.09.2018
Project no.:
A18-49
Commission:
Commission awarded on 06.08.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Haematology
Indication/Intervention:
Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors
Result of dossier assessment:
Conclusion of dossier assessment A18-20 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information
Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.
| Project no. | Title | Status |
|---|---|---|
| A18-20 | Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-09-20 A G-BA decision was published.